Agenus to present new bot/bal data in two presentations at aacr 2025

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology, today announced two upcoming presentations at the american association for cancer research (aacr) annual meeting, taking place april 25–30, 2025 in chicago, illinois. the presentations continue to build momentum for agenus' neoadjuvant immunotherapy program with botensilimab and balstilimab (bot/bal), including an oral presentation of the initial results from the neoasis trial in solid tumors and a poste.
AGEN Ratings Summary
AGEN Quant Ranking